Drug intelligence / Profile preview

XYZ-VII-69

Development stage: Preclinical
Lead developer: Florida Agricultural and Mechanical University
Modality: Small Molecules

Overview

XYZ-VII-69 is a novel small molecule sigma-2 receptor ligand developed at Florida A&M University. It is being investigated for its potential in treating solid tumors, particularly triple-negative breast cancer (TNBC). In preclinical studies, XYZ-VII-69 has demonstrated the ability to decrease cell viability, inhibit cell proliferation, induce apoptosis, and arrest cells at the G0/G1 phase of the cell cycle. Additionally, it has shown efficacy in preventing spheroid formation and disintegrating preformed spheroids in 3D culture assays, suggesting potential to halt tumor growth and prevent relapse.

Targets

TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))

Beyond the preview

Go deeper on XYZ-VII-69.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYZ-VII-69.

Explore the full profile